Dr. Leander Cannick
Claim this profileAnMed Health Cancer Center
Studies Cancer
Studies Anal Cancer
6 reported clinical trials
10 drugs studied
Area of expertise
1Cancer
Stage I
Stage II
LARS
2Anal Cancer
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Leander Cannick is currently running
HN-STAR
for Head and Neck Cancer
People who have been treated for head and neck cancer (HNC survivors) can experience serious consequences from their cancer and its treatment, ongoing risks of new cancers, and other unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors. Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health concerns before a routine visit with a cancer care provider. During the clinic visit, the provider uses HN-STAR to see evidence-based recommendations for managing each concern reported by the survivor. The provider and survivor discuss recommendations and select appropriate actions (e.g., testing, referrals, prescriptions, self-management). HN-STAR produces a survivorship care plan that includes all reported concerns and the actions selected in clinic. The survivorship care plan is given to the survivor and the primary care provider. Three months, six months, and nine months later, the survivor uses HN-STAR from home (or clinic) to report their concerns again, and a new survivorship care plan is created each time. Our trial randomizes 20-36 oncology practices from the National Community Oncology Research Program to use HN-STAR or provide usual care to 298-400 recent survivors of head and neck cancer. We hypothesize that survivors in the HN-STAR arm will have greater improvement in patient-centered outcomes (including cancer-related well-being, symptoms, and patient activation) over one year compared to survivors in the usual care arm, measured by surveys at baseline and one year later. We also hypothesize that survivors in the HN-STAR arm will be more likely to receive care that is aligned with evidence-based recommendations during the year of the study than survivors in the usual care arm. Our final aim investigates the implementation of HN-STAR in clinical practice, using interviews and surveys of survivors, providers, and other clinic staff to understand the feasibility, acceptability, appropriateness, and other aspects of providing survivorship care to head and neck cancer survivors.
Recruiting1 award N/A7 criteria
Reduced-Intensity Chemoradiation
for Anal Cancer
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Recruiting3 awards Phase 25 criteria
More about Leander Cannick
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Leander Cannick has experience with
- Fluorouracil
- Capecitabine
- Mitomycin
- Intensity-Modulated Radiation Therapy
- Dietary Intervention
- HN-STAR Intervention
Breakdown of trials Leander Cannick has run
Cancer
Squamous Cell Carcinoma
Anal Carcinoma
Anal Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Leander Cannick specialize in?
Leander Cannick focuses on Cancer and Anal Cancer. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage II.
Is Leander Cannick currently recruiting for clinical trials?
Yes, Leander Cannick is currently recruiting for 2 clinical trials in Anderson South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Leander Cannick has studied deeply?
Yes, Leander Cannick has studied treatments such as Fluorouracil, Capecitabine, Mitomycin.
What is the best way to schedule an appointment with Leander Cannick?
Apply for one of the trials that Leander Cannick is conducting.
What is the office address of Leander Cannick?
The office of Leander Cannick is located at: AnMed Health Cancer Center, Anderson, South Carolina 29621 United States. This is the address for their practice at the AnMed Health Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.